Extended Data Fig. 7: Individualized patient response to in vivo therapeutic targeting of XIAP, BCL2 and MCL1. | Nature Cancer

Extended Data Fig. 7: Individualized patient response to in vivo therapeutic targeting of XIAP, BCL2 and MCL1.

From: Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia

Extended Data Fig. 7

a,b, Individualized patient response to AZD5582-based combination therapy with (a) venetoclax and (b) S63845 are shown. Number of PDX models generated for each patient are presented above the panels. Significance of AML cell elimination was assessed by paired two-tailed t-test (PB) and unpaired two-tailed t-test (BM, SPL). PB, peripheral blood; BM, bone marrow; SPL, spleen; Pre, pre-treatment; Post, post-treatment.

Source data

Back to article page